Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Receivables (2016 - 2025)

Anaptysbio's Receivables history spans 9 years, with the latest figure at $33.8 million for Q4 2025.

  • For Q4 2025, Receivables fell 16.96% year-over-year to $33.8 million; the TTM value through Dec 2025 reached $33.8 million, down 16.96%, while the annual FY2025 figure was $33.8 million, 16.96% down from the prior year.
  • Receivables reached $33.8 million in Q4 2025 per ANAB's latest filing, down from $75.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $75.7 million in Q3 2025 to a low of $642000.0 in Q2 2021.
  • Average Receivables over 5 years is $12.0 million, with a median of $3.2 million recorded in 2023.
  • Peak YoY movement for Receivables: tumbled 75.06% in 2021, then surged 520.62% in 2025.
  • A 5-year view of Receivables shows it stood at $876000.0 in 2021, then soared by 61.99% to $1.4 million in 2022, then surged by 382.8% to $6.9 million in 2023, then surged by 495.02% to $40.8 million in 2024, then decreased by 16.96% to $33.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Receivables are $33.8 million (Q4 2025), $75.7 million (Q3 2025), and $21.4 million (Q2 2025).